Participated · Seed · Jun 2026

Build develops AI-driven infrastructure services that automate due diligence tasks such as site sourcing, technical checks, power assessments, risk planning and environmental analysis. The company operates on a retainer model—clients pay monthly for integrated assessments that aggregate and validate information from over 1,600 data sources, with human review before delivery. Build reports cutting due diligence timelines by more than 95%, turning processes that took weeks into hours, and has completed over 100 projects across 15 countries. Its client roster includes large real estate firms such as Tishman Speyer and a recently signed hyperscaler customer; it supports clients managing roughly $2 trillion in assets. Build has expanded to 10 employees across four continents and plans to hire additional engineers and industry experts as it scales. The company aims to move toward "agentic real estate," ultimately automating the full development lifecycle from site selection and permits through engineering, pre‑construction and asset management.

Led · Seed · Apr 2026

Ulysses builds underwater autonomous vehicles designed to map and monitor the oceans. The company is Irish co-founded and operates from San Francisco, with founders including Akhil V., Will O'Brien, Colm O'Brien and Jamie Wedderburn. It recently completed combined fundraising totaling $46 million (€39 million) from a seed round and a Series A. The Series A was led by Andreessen Horowitz and the seed by pebblebed. The article does not disclose revenue, user metrics, or a valuation. No specific product roadmap milestones or use-of-funds breakdown were reported.

Led · Equity · Feb 2026

Cognee is a Berlin-based AI infrastructure startup founded in 2024 that converts unstructured data into a persistent, graph-based memory layer for AI models and agents. Its technology enables systems to retain context over time, reason across connected information, and lower hallucination rates, addressing a core limitation of stateless retrieval and short context windows. Originally launched as an open-source project, Cognee has been adopted by thousands of developers, with more than 70 companies already running it in production, especially in knowledge-intensive and regulated sectors. The company is enhancing its core memory and graph engine while adding enterprise-grade reliability and scalability features. Cognee’s team operates across Europe and the United States and is positioning its platform as foundational infrastructure for global AI deployments. The recent €7.5 million raise provides capital to accelerate product development and support rising commercial demand.

Led · Series A · Dec 2025

Headquartered in San Francisco and led by CEO Jay Dawani, Lemurian Labs has built a platform that combines compiler technology with runtime orchestration to let developers write AI code once and deploy it on any hardware. Its hardware-agnostic approach promises faster deployment cycles, greater flexibility and lower infrastructure costs at scale. The company is positioning the platform for organizations seeking sustainable compute and open AI innovation. Fresh capital will be directed toward expanding the engineering team, accelerating product development and deepening partnerships across the AI ecosystem. Although specific revenue or user figures were not disclosed, the company previously completed a seed round in 2022. Lemurian Labs believes its technology can reduce the friction of moving AI workloads between edge devices, cloud instances and on-prem servers, potentially widening its addressable market.

Led · Seed · Nov 2025

Anomaly Bio is a Singapore-based biotechnology startup developing next-generation bio-based inputs by turning engineered microbes into ‘micro-factories.’ Using strain engineering and advanced fermentation, the company converts sugar into high-value ingredients for sectors such as crop protection, nutrition, and personal care. Its technology is positioned as a more resilient alternative to conventional agricultural and petrochemical supply chains that are increasingly disrupted by geopolitical and environmental shocks. With the fresh capital, Anomaly Bio plans to establish its own laboratory and pilot-scale facilities in Singapore while expanding its metabolic-engineering R&D team. The founders view the effort as aligned with Singapore’s national push for advanced biomanufacturing and “flexible multilateralism.” Prior to the current raise, the company collected more than $120,000 in non-dilutive awards from MIT’s WFA Prize 2025 and the WTFund Fellowship, as well as support from NUS and Mars Petcare’s Next Generation Pet Food Program. The team ultimately aims to build a globally competitive ingredients business powered by synthetic biology and on-demand production.